A Phase 1 interventional study of Baraclude in Hepatitis B Virus, sponsored by Bristol-Myers Squibb. Completed at 1 site in Japan. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-11-18.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies testing entecavir in Hepatitis B — 6 open to participants now, 9 under way, none of them phase 3. entecavir · Hepatitis B.
Among the 37 studies testing entecavir in Hepatitis B, this one is the 36th largest by enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2017, is one of 2 in phase 1, and was the 26th registered.
1,046 studies on the registry are indexed under Hepatitis B; 139 are open to participants now.
Browse Hepatitis B studies →6 of the 37 studies testing entecavir in Hepatitis B are open now, in 4 countries. Recruiting first, the newest first:
Bangladesh Medical University · Sites in Bangladesh
Ages 18+ · Men only
University Health Network, Toronto · Sites in Canada
Ages 18+
Ascentage Pharma Group Inc. · Sites in China
Ages 18+
Taichung Veterans General Hospital · Sites in Taiwan
Ages 20+
Qing-Lei Zeng
Ages 3–6
By country, each count listing its studies:
entecavir: first FDA approval 2005 (BARACLUDE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.
This study: 20 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 6 · Phase 4 20
First in 2001; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6 is below the median of 145 across 756 interventional studies indexed under Hepatitis B.
Median enrollment 106 across the 36 interventional studies. Of the 17 that completed or were terminated, 6 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 37 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
12 studies in Hepatitis B by Bristol-Myers Squibb: none open now, none under way, none of them phase 3. Of 11 finished, 5 (45%) have results posted.
Among the 12 studies in Hepatitis B by Bristol-Myers Squibb, this one is the only one that started in 2017, is the only one in phase 1, and was the 11th registered.
Bristol-Myers Squibb’s Hepatitis B studies by the year they started, since 2001.
3 of the studies testing entecavir in Hepatitis B that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05453435Sun Yat-sen UniversityEntecavir Prophylaxis for Hepatitis B Reactivation for CD20 Positive B-cell Lymphoma Patients With Resolved Hepatitis B (Negative Hepatitis B Surface Antigen, Positive Hepatitis B Core Antibody) | 2026-12 |
| NCT07816094Bangladesh Medical UniversityComparison of Viral Suppression With 0.5 mg and 1.0 mg Daily Doses of Entecavir in Decompensated HBV Cirrhosis of Liver | 2027-01-19 |
| NCT07189377University Health Network, TorontoCombined Light, ExVivo, and Antivirals for Recipients of Lungs From HBV Donors | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 37 studies testing entecavir in Hepatitis B, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 12 in Hepatitis B:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A Pharmacokinetics study of Baraclude in a real world clinical setting in Japan.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com.
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Baraclude
Specified dose on specified day
Maximum Observed Plasma Concentration (Cmax)
Cmax is defined as the peak plasma concentration
Time frame: Up to 24 hours
Time of Maximum Observed Plasma Concentration (Tmax)
Tmax is defined as the time of maximum observed plasma concentration, measured in hours
Time frame: Up to 24 hours
Trough Observed Plasma (Predose) Concentration (Ctrough)
Ctrough is defined as the trough in observed plasma (predose) concentrations
Time frame: prior to administration of drug (predose)
Observed Plasma Concentration at 24 Hours Postdose (C24)
C24 is defined as the observed plasma concentration at 24 hours post-dose
Time frame: 24 hours post-dose
Area Under the Concentration-time Curve in One Dosing Interval [AUC(TAU)]
AUC(TAU) is defined as the area under the concentration-time curve in one dosing interval
Time frame: Up to 24 hours
Apparent Total Body Clearance (CLT/F)
CLT/F is defined as the apparent total body clearance
Time frame: Up to 24 hours
| Milestone | Baraclude |
|---|---|
| Started | 6 |
| Completed | 6 |
| Not completed | 0 |
Cmax is defined as the peak plasma concentration
| ng/mL | Baraclude |
|---|---|
| Maximum Observed Plasma Concentration (Cmax) | 8.17 ± 2.517 |
Tmax is defined as the time of maximum observed plasma concentration, measured in hours
| Hours | Baraclude |
|---|---|
| Time of Maximum Observed Plasma Concentration (Tmax) | 0.667 ± 0.2582 |
Ctrough is defined as the trough in observed plasma (predose) concentrations
| ng/mL | Baraclude |
|---|---|
| Trough Observed Plasma (Predose) Concentration (Ctrough) | 0 ± 0 |
C24 is defined as the observed plasma concentration at 24 hours post-dose
| ng/mL | Baraclude |
|---|---|
| Observed Plasma Concentration at 24 Hours Postdose (C24) | 0.435 ± 0.0678 |
AUC(TAU) is defined as the area under the concentration-time curve in one dosing interval
| h*ng/mL | Baraclude |
|---|---|
| Area Under the Concentration-time Curve in One Dosing Interval [AUC(TAU)] | 21.8 ± 4.53 |
CLT/F is defined as the apparent total body clearance
| mL/min | Baraclude |
|---|---|
| Apparent Total Body Clearance (CLT/F) | 397 ± 81.7 |
Collected over AE information should begin at initiation of study treatment until 100 days after discontinuation. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Baraclude | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Age, Continuous(Years) | Baraclude |
|---|---|
| Mean | 55.0 ± 9.96 |
| Sex: Female, Male(Participants) | Baraclude |
|---|---|
| Female | 1 |
| Male | 5 |
| Race/Ethnicity, Customized(Participants) | Baraclude |
|---|---|
| Number | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2017 to primary completion in Dec 2017, 7 months.
Results were first posted in Nov 2023, 5 years 10 months after primary completion.
Of 49 industry-sponsored phase 1 interventional studies under Hepatitis B, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 24. This study's 7 months is below that.
Counting every sponsor, half of 58 studies reached it within 14 months; a quarter within 7 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Entecavir